Impacts of Intensive Insulin Therapy in Patients Undergoing Heart Valve Replacement
DOI:
https://doi.org/10.1532/HSF98.20101017Abstract
Background and Aims: Cardiac surgery with cardioplegic cardiac arrest and cardiopulmonary bypass (CPB) is associated with severe stress response, systemic inflammatory response, and injury. This study was designed to investigate the effects of intensive insulin therapy on patients undergoing valve replacement with CPB.
Methods: One hundred nondiabetic inpatients undergoing valve replacement were randomly assigned to a control group or an intensive insulin therapy (IT) group. Plasma cytokine and cardiac troponin I (cTnI) levels were monitored perioperatively.
Results: Compared with the control group, the IT group had smaller increases in plasma concentrations of tumor necrosis factor ?, interleukin 1? (IL-1?), IL-6, and cTnI, and had a more pronounced increase in IL-10 levels after the initiation of CPB. After surgery, the required inotropes were reduced in the IT group. In the IT group, the time of artificial ventilation and the postoperative length of stay in the hospital were markedly shortened; however, there were no significant differences between the IT and control groups in mortality and the rate of nosocomial infections of deep sternal wounds.
Conclusions: IT can significantly attenuate the systemic inflammatory response and improve a damaged cardiac function, but it does not reduce the in-hospital mortality rate.
References
Aebert H, Kirchner S, Keyser A, et al. 2000. Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass. Eur J Cardiothorac Surg 18:589-93.nAsahara T, Masuda H, Takahashi T, et al. 1999. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-8.nCollard CD, Gelman S. 2001. Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury. Anesthesiology 94:1133-8.nDandona P, Aljada A, Mohanty P. 2002. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 45:924-30.nDas UN. 2006. Pyruvate is an endogenous anti-inflammatory and anti-oxidant molecule. Med Sci Monit 12:RA79-84.nDas UN. 2006. Glucose, insulin, and acute myocardial infarction. Eur Heart J 27:2141-3.nDoenst T, Wijeysundera D, Karkouti K, et al. 2005. Hyperglycemia during cardiopulmonary bypass is an independent risk factor for mortality in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 130:1144-51.nFurnary AP, Wu Y. 2006. Clinical effects of hyperglycemia in the cardiac surgery population: the Portland Diabetic Project. Endocr Pract 12:22-6.nGolden SH, Peart-Vigilance C, Kao WH, Brancati FL. 1999. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 22:1408-14.nGriesdale DE, de Souza RJ, van Dam RM, et al. 2009. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 180:821-7.nGu CH, Cui Q, Wang YY, et al. 2008. Effects of insulin therapy on inflammatory mediators in infants undergoing cardiac surgery with cardiopulmonary bypass. Cytokine 44:96-100.nGu CH, Wei XF, Wang YY, et al. 2008. No infection with porcine endogenous retrovirus in recipients of acellular porcine aortic valves: a two-year study. Xenotransplantation 15:121-8.nHa H, Yu MR, Choi YJ, Kitamura M, Lee HB. 2002. Role of high glucose-induced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13:894-902.nJeschke MG, Klein D, Bolder U, Einspanier R. 2004. Insulin attenuates the systemic inflammatory response in endotoxemic rats. Endocrinology 145:4084-93.nKoh TW, Hooper J, Kemp M, Ferdinand FD, Gibson DG, Pepper JR. 1998. Intraoperative release of troponin T in coronary venous and arterial blood and its relation to recovery of left ventricular function and oxidative metabolism following coronary artery surgery. Heart 80:341-8.nLazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. 2004. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation 109:1497-502.nRassias AJ. 2006. Intraoperative management of hyperglycemia in the cardiac surgical patient. Semin Thorac Cardiovasc Surg 18:330-8.nShilling AM, Raphael J. 2008. Diabetes, hyperglycemia, and infections. Best Pract Res Clin Anaesthesiol 22:519-35.nShore S, Nelson DP, Pearl JM, et al. 2001. Usefulness of corticosteroid therapy in decreasing epinephrine requirements in critically ill infants with congenital heart disease. Am J Cardiol 88:591-4.nTaylor JH, Beilman GJ. 2005. Hyperglycemia in the intensive care unit: no longer just a marker of illness severity. Surg Infect (Larchmt) 6:233-45.nTracey KJ, Fong Y, Hesse DG, et al. 1987. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662-4.nTripathy D, Mohanty P, Dhindsa S, et al. 2003. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 52:2882-7.nvan den Berghe G, Wilmer A, Hermans G, et al. 2006. Intensive insulin therapy in the medical ICU. N Engl J Med 354:449-61.nvan den Berghe G, Wouters P, Weekers F, et al. 2001. Intensive insulin therapy in critically ill patients. N Engl J Med 345:1359-67.nWang H, Bloom O, Zhna M, et al. 1999. HMG-1 as a late mediator of endotoxin lethality in mice. Science 285:248-51.n
